Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2012

Open Access 01-12-2012 | Case report

Acute kidney injury after ingestion of rhubarb: secondary oxalate nephropathy in a patient with type 1 diabetes

Authors: Marc Albersmeyer, Robert Hilge, Angelika Schröttle, Max Weiss, Thomas Sitter, Volker Vielhauer

Published in: BMC Nephrology | Issue 1/2012

Login to get access

Abstract

Background

Oxalosis is a metabolic disorder characterized by deposition of oxalate crystals in various organs including the kidney. Whereas primary forms result from genetic defects in oxalate metabolism, secondary forms of oxalosis can result from excessive intestinal oxalate absorption or increased endogenous production, e.g. after intoxication with ethylene glycol.

Case presentation

Here, we describe a case of acute crystal-induced renal failure associated with excessive ingestion of rhubarb in a type 1 diabetic with previously normal excretory renal function. Renal biopsy revealed mild mesangial sclerosis, but prominent tubular deposition of oxalate crystals in the kidney. Oxalate serum levels were increased.

Conclusion

Acute secondary oxalate nephropathy due to excessive dietary intake of oxalate may lead to acute renal failure in patients with preexisting renal disease like mild diabetic nephropathy. Attention should be payed to special food behaviors when reasons for acute renal failure are explored.
Appendix
Available only for authorised users
Literature
1.
Hoppe B: The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type III. Nephrol Dial Transplant. 2012, 27: 3024-3026. 10.1093/ndt/gfs308.CrossRefPubMed
2.
Hoppe B: An update on primary hyperoxaluria. Nat Rev Nephrol. 2012, 8: 467-475. 10.1038/nrneph.2012.113.CrossRefPubMed
3.
Siva S, Barrack ER, Reddy GPV, Thamilselvan V, Thamilselvan S, Menon M, Bhandari M: A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2009, 103: 18-21. 10.1111/j.1464-410X.2008.08122.x.CrossRefPubMed
4.
Bobrowski AE, Langman CB: Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother. 2006, 7: 1887-1896. 10.1517/14656566.7.14.1887.CrossRefPubMed
5.
6.
Rodman JS, Mahler RJ: Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am. 2000, 27: 275-285. 10.1016/S0094-0143(05)70257-3. viiiCrossRefPubMed
7.
Noonan S: Oxalate content of foods and its effect on humans. Asia Pacific J Clin Nutr. 1999, 8: 64-74. 10.1046/j.1440-6047.1999.00038.x.CrossRef
8.
Tsai J-J, Huang CW, Wu J-K, Tony T, Lee Y: Comparison of oxalate content in foods and beverages in Taiwan. J Taiwan Urol Assoc. 2005, 16: 93-99.
9.
Peng A, Gu Y, Lin SY: Herbal treatment for renal diseases. Ann Acad Med Singap. 2005, 34: 44-51.PubMed
10.
Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A, Ribes D, Rostaing L, Chauveau D, Giraud P: Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011, 6: 1895-1902. 10.2215/CJN.00010111.CrossRefPubMedPubMedCentral
11.
Moutzouris D-A, Skaneli G, Margellos V, Apostolou T, Petraki C, Nikolopoulou N: Oxalate nephropathy in a diabetic patient after gastric by-pass. Clin Nephrol. 2011, 75 (Suppl 1): 16-19.PubMed
12.
Lefaucheur C, Hill GS, Amrein C, Haymann JP, Jacquot C, Glotz D, Nochy D: Acute oxalate nephropathy: a new etiology for acute renal failure following nonrenal solid organ transplantation. Am J Transplant. 2006, 6: 2516-2521. 10.1111/j.1600-6143.2006.01485.x.CrossRefPubMed
13.
Chen CL, Fang HC, Chou KJ, Wang JS, Chung HM: Acute oxalate nephropathy after ingestion of star fruit. Am J Kidney Dis. 2001, 37: 418-422. 10.1053/ajkd.2001.21333.CrossRefPubMed
14.
Sasaki M, Murakami M, Matsuo K, Matsuo Y, Tanaka S, Ono T, Mori N: Oxalate nephropathy with a granulomatous lesion due to excessive intake of peanuts. Clin Exp Nephrol. 2008, 12: 305-308. 10.1007/s10157-008-0046-5.CrossRefPubMed
15.
Sanz P, Reig R: Clinical and pathological findings in fatal plant oxalosis. A review. Am J Forensic Med Pathol. 1992, 13: 342-345. 10.1097/00000433-199212000-00016.CrossRefPubMed
16.
Holmes RP, Ambrosius WT, Assimos DG: Dietary oxalate loads and renal oxalate handling. J Urol. 2005, 174: 943-947. 10.1097/01.ju.0000169476.85935.e2.CrossRefPubMed
17.
Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F: Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant. 1993, 8: 1333-1337.PubMed
18.
Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H: Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006, 70: 1305-1311. 10.1038/sj.ki.5001707.CrossRefPubMed
19.
Lieske JC, Tremaine WJ, De Simone C, O’Connor HM, Li X, Bergstralh EJ, Goldfarb DS: Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010, 78: 1178-1185. 10.1038/ki.2010.310.CrossRefPubMedPubMedCentral
20.
Illies F, Bonzel K-E, Wingen A-M, Latta K, Hoyer PF: Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006, 70: 1642-1648. 10.1038/sj.ki.5001806.CrossRefPubMed
21.
Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB: Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis. 2011, 58: 453-455. 10.1053/j.ajkd.2011.05.012.CrossRefPubMed
22.
Borghi L, Nouvenne A, Meschi T: Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin?. Kidney Int. 2010, 78: 1063-1065. 10.1038/ki.2010.345.CrossRefPubMed
Metadata
Title
Acute kidney injury after ingestion of rhubarb: secondary oxalate nephropathy in a patient with type 1 diabetes
Authors
Marc Albersmeyer
Robert Hilge
Angelika Schröttle
Max Weiss
Thomas Sitter
Volker Vielhauer
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2012
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-13-141

Other articles of this Issue 1/2012

BMC Nephrology 1/2012 Go to the issue

Research article

Association between serum insulin-like growth factor I or IGF-binding protein 3 and estimated glomerular filtration rate: results of a population-based sample

Research article

Effect of add-on direct renin inhibitor aliskiren in patients with non-diabetes related chronic kidney disease

Research article

Cardiovascular determinants of prognosis in normotensive hemodialysis patients

Research article

Association of pre-transplant statin use with delayed graft function in kidney transplant recipients

Research article

The MDRD equation underestimates the prevalence of CKD among blacks and overestimates the prevalence of CKD among whites compared to the CKD-EPI equation: a retrospective cohort study

Study protocol

Predicting the outcome of chronic kidney disease by the estimated nephron number: The rationale and design of PRONEP, a prospective, multicenter, observational cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits